Security key
48576U106
Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI)
CUSIP: 48576U106
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 27,985
- Total 13F value
- $183,022
- Share change
- 0
- SEC-reported price per share
- $6.54
- Number of holders
- 1
- Shares outstanding
- 22,658,403
Holder snapshot
3 signals
Security identity
1 source field
Report period
Q3 2025
Institutions
1
Top holders
1
KPTI full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2025
Previous quarter: Q2 2025
Karyopharm Therapeutics Inc. SEC filings
Karyopharm Therapeutics Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 48576U106
Recent filing periods:
Ownership snapshot
Top reported holders of KPTI - Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
HIGHBRIDGE CAPITAL MANAGE...
Disclosed value leader
HIGHBRIDGE CAPITAL MANAGE...
Comparable rows
15/15
Latest evidence
30 Sep 2025
13D/G
13F
Lead comparable stake: 4.9%
13D/G row: HIGHBRIDGE CAPITAL MANAGEMENT LLC
Showing 1-6 of 15 holder rows.
Quick read
HIGHBRIDGE CAPITAL MANAGEMENT LLC leads the comparable SEC ownership view at 4.9%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Comparable ownership
Top 5
HIGHBRIDGE CAPITAL MANAGEMENT LLC
4.9%
JPMORGAN CHASE & CO
4.9%
VANGUARD GROUP INC
4.7%
T. Rowe Price Investment Manageme...
3.8%
ADAGE CAPITAL PARTNERS GP, L.L.C.
2.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| HIGHBRIDGE CAPITAL MANAGEMENT LLC |
13D/G
|
4.9%
|
$4,250,895
649,984 shares
|
$0 | 30 Sep 2025 |
| JPMORGAN CHASE & CO |
13D/G
13F
Company
|
4.9%
|
$2,797,089
427,624 shares
|
-$149,213 | 30 Sep 2025 |
| VANGUARD GROUP INC |
13D/G
13F
The Vanguard Group · Company
|
4.7%
|
$2,670,221
408,222 shares
|
$0 | 30 Sep 2025 |
| T. Rowe Price Investment Management, Inc. |
13F
Company
|
3.8%
|
$3,141,000
728,766 shares
|
— | 30 Jun 2025 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
Company
|
2.2%
|
$1,815,898
421,322 shares
|
— | 30 Jun 2025 |
| Eversept Partners, LP |
13F
Company
|
1.4%
|
$1,108,334
257,154 shares
|
— | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
27,985
Rows available
1
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
1
Q3 2025 holders
1
Holder diff
0
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 value | Q3 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend